TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19088953

Group type: EXPERIMENTAL
Intervention: External bleaching with Illumine office (30% hydrogen peroxide) for 60 minutes followed by home bleaching with Illumine home (15% carbamide peroxide) for 2 weeks with daily bleaching time of 1 hour
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no bleaching treatment)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: External bleaching with Illumine office (30% hydrogen peroxide) followed by home bleaching
Number of subjects: 18
Study: 16532017

Group type: EXPERIMENTAL
Intervention: Increased bone marrow iron stores (BMIS) prior to ASCT
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Duration of severe neutropenia post-ASCT (<100 ANC/microl)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Increased BMIS (multivariate analysis)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Smoking (multivariate analysis)
Number of subjects: 367
Study: 12649049

Group type: COMPARATOR
Intervention: Basic Internet-based, information-focused intervention
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Tailored self-management training
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Peer support components
Number of subjects: 320
Study: 10749297

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol administered two times weekly (G-2/w)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol administered three times weekly (G-3/w)
Number of subjects: 22
Study: 8767977

Group type: EXPERIMENTAL
Intervention: Oral amtolmetineguacyl 600 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7840914

Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 467

Group type: COMPARATOR
Intervention: Zalcitabine
Number of subjects: 467
Study: 3358822

Group type: EXPERIMENTAL
Intervention: Oral thiamin supplementation (250 mg daily for 5 days)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Parenteral thiamin supplementation (250 mg daily for 5 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Parenteral thiamin supplementation (250 mg within 24 hr)
Number of subjects: 25
Study: 29490101

Group type: EXPERIMENTAL
Intervention: Omega‐3‐6‐9 Junior (Nordic Naturals, Inc.) treatment (338 mg eicosapentaenoic acid, 225 mg DHA, and 83 mg GLA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Canola oil (124 mg palmitic acid, 39 mg stearic acid, 513 mg linoleic acid, 225 mg α‐linolenic acid, and 1346 mg oleic acid)
Number of subjects: 31
Study: 28628702

Group type: EXPERIMENTAL
Intervention: Financial incentives (coupons redeemable for $125 cash-equivalent gift cards upon linkage to care)
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Financial incentives ($70 gift cards quarterly for viral suppression)
Number of subjects: 1061
Study: 24357856

Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 20
Study: 22156973

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 5567

Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA)
Number of subjects: 5567

Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate (Net-En)
Number of subjects: 5567

Group type: COMPARATOR
Intervention: Nonhormonal contraceptives (Control)
Number of subjects: 5567

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) among young women (16-24 years)
Number of subjects: 5567

Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA) among young women (16-24 years)
Number of subjects: 5567

Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate (Net-En) among young women (16-24 years)
Number of subjects: 5567
Study: 19847011

Group type: EXPERIMENTAL
Intervention: Parenting programme from age 8 to 15 months, with two group sessions co-led by well-child providers and a parenting expert.
Number of subjects: 733

Group type: COMPARATOR
Intervention: Control: Usual primary care.
Number of subjects: 733
Study: 17400486

Group type: EXPERIMENTAL
Intervention: Dacron grafts
Number of subjects: 413

Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Dacron and PTFE grafts
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Critical limb ischemia patients
Number of subjects: 413
Study: 15757860

Group type: EXPERIMENTAL
Intervention: High FFA trial (HFA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low FFA trial (LFA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both trials (HFA and LFA)
Number of subjects: 10
Study: 11877270

Group type: EXPERIMENTAL
Intervention: Pegylated Escherichia coli asparaginase (pegaspargase)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Native Escherichia coli asparaginase
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 118
Study: 9428849

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microgram/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil 2 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil 3 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil 4 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil 3-4 micrograms/kg and propofol 2 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil 3 micrograms/kg and propofol 2 mg/kg
Number of subjects: 80
Study: 8291918

Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan hydrochloride) regimen B (40 mg/m2 for 5 days every 3-4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan hydrochloride) regimen C (40 mg/m2 for 3 days every week)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan hydrochloride) regimen D (20 mg/m2 twice a day for 7 days every 3-4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan hydrochloride) regimen A (200 mg/m2 once a day every 3-4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan hydrochloride)
Number of subjects: 30
Study: 3234233

Group type: EXPERIMENTAL
Intervention: Men drink group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Women drink group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 31962350

Group type: EXPERIMENTAL
Intervention: High-tension HS group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low-tension HS group
Number of subjects: 90
Study: 29191543

Group type: EXPERIMENTAL
Intervention: 1-level interbody fusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: multilevel interbody fusion
Number of subjects: 100
Study: 28657784

Group type: EXPERIMENTAL
Intervention: IFN-γ‐1b
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emphysema extent greater than or equal to 15%
Number of subjects: 0

Group type: COMPARATOR
Intervention: No emphysema or emphysema less than 15%
Number of subjects: 0
Study: 26330032

Group type: EXPERIMENTAL
Intervention: Peer instruction
Number of subjects: 101
Study: 23276475

Group type: EXPERIMENTAL
Intervention: Admission heart rate (HR) ≥95 beats/min
Number of subjects: 211

Group type: COMPARATOR
Intervention: Admission heart rate (HR) <95 beats/min
Number of subjects: 211
Study: 20974547

Group type: EXPERIMENTAL
Intervention: Solution A (Solo‐care Aqua(®), Ciba‐Vision)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Solution B (Hidro Health(®), Disop)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Baseline visit
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both solutions
Number of subjects: 54
Study: 18318715

Group type: EXPERIMENTAL
Intervention: Functional fermented milk containing borage oil, green tea, and vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 0
Study: 17065352

Group type: EXPERIMENTAL
Intervention: 1,000 mg uric acid i.v. in vehicle
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1,000 mg vitamin C as a control antioxidant
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 24
Study: 12948313

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5% timolol twice daily
Number of subjects: 30
Study: 10999496

Group type: EXPERIMENTAL
Intervention: dimenhydrinate-1 atm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: dimenhydrinate-3 atm
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo-1 atm
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo-3 atm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: dimenhydrinate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: depth
Number of subjects: 30
Study: 9286047

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines containing genetically detoxified PT
Number of subjects: 0
Study: 1390504

Group type: EXPERIMENTAL
Intervention: Aspirin 1200 mg/day
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/day
Number of subjects: 2435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2435
Study: 4009497

Group type: EXPERIMENTAL
Intervention: Urinary acidification (pH 4.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary alkalinization (pH 6.7)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment (urine pH 5.6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acid loading
Number of subjects: 0
Study: 31675689

Group type: EXPERIMENTAL
Intervention: Multimodal treatment (embolization, surgery, and/or proton beam radiosurgery)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Multimodal treatment
Number of subjects: 318
Study: 30543598

Group type: EXPERIMENTAL
Intervention: Dual checkpoint inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VEGF inhibition combined with checkpoint inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies of checkpoint inhibitors of different classes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previously approved treatments
Number of subjects: 0
Study: 27509101

Group type: EXPERIMENTAL
Intervention: Frozen-embryo transfer
Number of subjects: 1508
Study: 24820535

Group type: EXPERIMENTAL
Intervention: Telemedicine-based treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional hospitalization
Number of subjects: 44
Study: 22570023

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol nail lacquer
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1% clobetasol nail lacquer
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 8% clobetasol nail lacquer
Number of subjects: 15

Group type: COMPARATOR
Intervention: Base coat nail lacquer (control)
Number of subjects: 15
Study: 19996621

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg, 2 h before surgery)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 90
Study: 17932151

Group type: EXPERIMENTAL
Intervention: Maximal ergometer rowing with room air
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Maximal ergometer rowing with inspired O2 fraction of 0.17
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Maximal ergometer rowing with inspired O2 fraction of 0.30
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Maximal ergometer rowing
Number of subjects: 6
Study: 16133961

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg daily
Number of subjects: 80
Study: 11809180

Group type: EXPERIMENTAL
Intervention: Omeprazole triple therapy (eradication group) for 1 week, followed by diclofenac slow release 100 mg daily for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Omeprazole with placebo antibiotics (placebo group) for 1 week, followed by diclofenac slow release 100 mg daily for 6 months
Number of subjects: 100
Study: 11864514

Group type: EXPERIMENTAL
Intervention: Calcium intake of 550 +/- 150 mg/d
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Calcium intake of 900 +/- 150 mg/d
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Calcium intake of 1500 +/- 150 mg/d
Number of subjects: 35
Study: 7805900

Group type: EXPERIMENTAL
Intervention: High spermatic vein ligation (group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High spermatic vein ligation (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (nonoperated group A)
Number of subjects: 20
Study: 1952472

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 140
Study: 6293719

Group type: EXPERIMENTAL
Intervention: Cefotaxime perioperatively
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Cefotaxime perioperatively and 24 hours postoperatively
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Cefazolin perioperatively and 24 hours postoperatively
Number of subjects: 118
Study: 31770287

Group type: EXPERIMENTAL
Intervention: Propofol-based total intravenous anesthesia (TIVA group, n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Desflurane anesthesia (DES group, n=25)
Number of subjects: 50
Study: 27885786

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (6 g/d for 8 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Medium chain triglycerides (MCT) oil (6 g/d for 8 weeks)
Number of subjects: 38
Study: 25869389

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 5 mg once daily for 4 weeks, then every other day for an additional 4 weeks
Number of subjects: 282

Group type: COMPARATOR
Intervention: Prednisone (PD) 40 mg once daily for the initial 2 weeks, tapered by 10 mg every 2 weeks during the 8-week study period
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Prednisone (PD)
Number of subjects: 282
Study: 24805910

Group type: EXPERIMENTAL
Intervention: Higher task self-efficacy for resistance training
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Greater goal-setting behaviour
Number of subjects: 330
Study: 21107314

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intersection‐union test (IUT)
Number of subjects: 0
Study: 19847078

Group type: EXPERIMENTAL
Intervention: Plasma Kinetic loop Resection of the Prostate (PKRP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional monopolar transurethral resection of prostate (TURP)
Number of subjects: 102
Study: 16461169

Group type: EXPERIMENTAL
Intervention: Chiropractic care combined with moist hot pack
Number of subjects: 252

Group type: COMPARATOR
Intervention: Moist heat alone
Number of subjects: 252
Study: 14758179

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus intravascular catheter-based heat exchange system (Alsius, Irvine, CA)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Conventional treatment (acetaminophen and cooling blankets)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Catheter-based heat exchange system
Number of subjects: 296
Study: 11419818

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg once daily for 20 wk
Number of subjects: 593

Group type: COMPARATOR
Intervention: ranitidine 150 mg b.i.d. for 20 wk
Number of subjects: 593

Group type: COMPARATOR
Intervention: ranitidine 150 mg b.i.d. for 8 wk followed by lansoprazole 30 mg once daily for 12 wk ('step-up')
Number of subjects: 593

Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 8 wk followed by ranitidine 150 mg b.i.d. for 12 wk ('step-down')
Number of subjects: 593
Study: 9425645

Group type: EXPERIMENTAL
Intervention: Wisconsin test battery - gap detection sensory test
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Wisconsin test battery - rapid pinch and release psychomotor test
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of both tests
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Stepwise discriminant analysis
Number of subjects: 18
Study: 8474318

Group type: EXPERIMENTAL
Intervention: 23 g parboiled white rice
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 46 g parboiled white rice
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 69 g parboiled white rice
Number of subjects: 3
Study: 2881131

Group type: EXPERIMENTAL
Intervention: Cyclosporin for 3 months followed by conversion to azathioprine and prednisolone
Number of subjects: 129

Group type: COMPARATOR
Intervention: Conventional therapy (azathioprine and prednisolone)
Number of subjects: 129
Study: 31058475

Group type: EXPERIMENTAL
Intervention: Computerized evaluation and re‐education biofeedback (CERB)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Home‐based program (tendon gliding exercise and resistive exercise)
Number of subjects: 38
Study: 29865281

Group type: EXPERIMENTAL
Intervention: LCD + INT (1200 kcal/day + 60 min/day alternating 3 min at 90 and 50% HRpeak)
Number of subjects: 26

Group type: COMPARATOR
Intervention: LCD (1200 kcal/day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both interventions (LCD and LCD + INT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: LCD + INT
Number of subjects: 26
Study: 27400028

Group type: EXPERIMENTAL
Intervention: Tailored educational supportive care programme
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 84
Study: 24635951

Group type: EXPERIMENTAL
Intervention: Hypnoanalgesia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Previous PDT without hypnosis
Number of subjects: 12
Study: 22689676

Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous bortezomib
Number of subjects: 0
Study: 20107198

Group type: EXPERIMENTAL
Intervention: High Fat diet (low-carbohydrate diet < or =20 g/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: High Carb diet (calorie-restricted, low-fat diet, 55% of total energy intake)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 18046669

Group type: EXPERIMENTAL
Intervention: 4.0 g daily sevelamer dose
Number of subjects: 27

Group type: COMPARATOR
Intervention: 1.2 g daily sevelamer dose
Number of subjects: 27
Study: 16189090

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ER 500 mg once daily for 3 days
Number of subjects: 523

Group type: COMPARATOR
Intervention: Ciprofloxacin IR 250 mg twice daily for 3 days
Number of subjects: 523
Study: 11850133

Group type: EXPERIMENTAL
Intervention: General alcohol and cocaine use patterns (on days not involving significant interpersonal conflict)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Alcohol and cocaine use on the day of the violent incident
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Higher drinking levels
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Minority status
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Interaction of alcohol and cocaine use
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Routine screening and intervention approaches for violence-related problems
Number of subjects: 250
Study: 11482127

Group type: EXPERIMENTAL
Intervention: Case management plus regular Medicare benefits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular benefits only
Number of subjects: 0
Study: 8706193

Group type: EXPERIMENTAL
Intervention: Reinforced laryngeal mask (RLM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Endotracheal tube (ET)
Number of subjects: 100
Study: 2208013

Group type: EXPERIMENTAL
Intervention: Oophorectomy plus cyclophosphamide or combination chemotherapy
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Oophorectomy plus combination chemotherapy
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Immediate combination chemotherapy
Number of subjects: 378

Group type: COMPARATOR
Intervention: Combination chemotherapy
Number of subjects: 378
Study: 352507

Group type: COMPARATOR
Intervention: CP (cyclophosphamide 1 g/m2 on day 1 and prednisone 100 mg/m2 daily for five days)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: CVP (CP plus vincristine 1 mg/m2 on day 1)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: BCVP (CVP plus BCNU 60 mg/m2 on day 1)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: CVP
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: BCVP
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: CP
Number of subjects: 187
Study: 31377707

Group type: EXPERIMENTAL
Intervention: Health-promoting apartment design requirements
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Higher policy compliance (overall and by design theme)
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Environmental stressors
Number of subjects: 1099
Study: 28932995

Group type: EXPERIMENTAL
Intervention: rE-4 10 μg twice a day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Exenatide 10 μg twice a day (Control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: rE-4 with metformin
Number of subjects: 36
Study: 26045549

Group type: EXPERIMENTAL
Intervention: Delayed start protocol (Gn then Cetrotide 0.25 mg sc added when leading follicle reaches >12 mm)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional GnRH antagonist protocol (Cetrotide 0.25 mg sc from day 2 to day 8, then Gn therapy added)
Number of subjects: 160
Study: 24453922

Group type: EXPERIMENTAL
Intervention: Workplace noise exposure
Number of subjects: 555
Study: 21606537

Group type: EXPERIMENTAL
Intervention: ABC-3TC
Number of subjects: 269

Group type: COMPARATOR
Intervention: TDF-FTC
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: EFV
Number of subjects: 269

Group type: COMPARATOR
Intervention: ATV/r
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 269
Study: 19117121

Group type: EXPERIMENTAL
Intervention: 1 g etofenamate (group 1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.9% saline (group 2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 70
Study: 16076380

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride 2250 mg/day
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride 3000 mg/day
Number of subjects: 65
Study: 12240756

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 30
Study: 10072008

Group type: EXPERIMENTAL
Intervention: Spinal sufentanil 7.5 microg + bupivacaine 2.5 mg + clonidine 50 microg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spinal sufentanil 7.5 microg + bupivacaine 2.5 mg
Number of subjects: 30